Hundreds of vaping product companies have been warned that they lack FDA requirements.
The US Food and Drug Administration (FDA) is stepping up its efforts to regulate the business of vaping products.
The agency’s Center for Tobacco Products (CTP) has outlined steps it plans to take to further prevent the public health harm it says e-cigarettes pose to youth.
DO NOT MISS: US Government makes a decision on CBD
“As we enter this era of declining use of combustible tobacco and continued innovation in the e-cigarette industry, societal concerns are not subtle,” FDA Food and Drug Commissioner Robert Califf said in a statement. release. statement February 24th. “Our ability to keep pace with these changes will depend on the immediate, short-term, and long-term actions the center is taking that we believe will position the agency to more successfully implement our regulatory oversight of tobacco products.”
The FDA cites its review process for pending applications for e-cigarette products as an area of focus.
“As the agency continues to make progress in its review of new and pending applications for novelty products such as e-cigarettes, the FDA will take additional steps to remove illegal products from the market, particularly those that have led to e-cigarettes being the most widely used tobacco product among youth,” the statement said.
The street
Marlboro maker Philip Morris (P.M) – Get a free reportis an increasingly important player in the electronic cigarette market.
“Philip Morris is well ahead of its peers in reduced-risk products, which the company expects to be the majority of its business by 2025,” according to Barron’s. “They already account for nearly 30% of sales, compared to about 15% for Altria Group. (month) – Get a free reportand British American Tobacco (BTAFF) .”
For now, the CTP targets e-cigarette companies whose products lack the required FDA marketing authorization.
“Between January 2021 and February 17, 2023, the FDA issued more than 550 warning letters to companies for continuing to sell e-cigarette products that lacked the FDA-required marketing authorization,” the statement said. “These companies had millions of products listed with the FDA.”
“After receiving warning letters, most of these companies complied and withdrew their products from the market. However, in cases where the companies did not, the FDA may take further enforcement action.”
